skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

12 Total results for product and free and sample content found

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

18 Oct 2019

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic cell-and-gene-therapy drug-development-landscape

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

18 Oct 2019

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.

Topic Cell and gene therapy

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Webinar: Manufacturing Challenges Facing Cell and Gene Therapy

27 Sep 2019

As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.

Topic cell-and-gene-therapy

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges

11 Jun 2019

J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges

News and notes from the 2019 J.P. Morgan Healthcare Conference. Pfizer CEO Bourla underscores need for scientific and commercial innovation, Gilead makes M&A a priority, Novartis' new R&D chief reflects on first meeting with CEO Narasimhan, Sarepta CEO Ingram clarifies regulatory path for micro-dystrophin, J.P. Morgan outlines deal and macro biopharma trends in 2019, and cell therapy panel discusses manufacturing challenges.

Topic BioPharmaceutical Cell and gene therapy

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Gene Therapy: A Paradigm Shift in Medicine

10 Apr 2019

The following analysis reviews several aspects of the gene therapy market. The history of gene therapy is briefly discussed, alongside a look at the trend in the volume of candidates in development over the past 20+ years, and how the regulatory landscape in the US and EU has recently adapted to help move the field forward. A deep dive into the pipeline with  breakdowns by delivery method and therapy area is provided, as are the key companies involved and the major partnership deals that have made gene therapy a hot commodity. Manufacturing, pricing, and reimbursement issues are also addressed.

Topic cell-and-gene-therapy

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Bayer Bosses Beg Risk-Averse Europe To Rethink

By Kevin Grogan 07 Mar 2019

Bayer Bosses Beg Risk-Averse Europe To Rethink

The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.

Topic cell-and-gene-therapy

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Competitive Strategies Critical As EMA Decides On Kymriah And Yescarta

22 Aug 2018

Competitive Strategies Critical As EMA Decides On Kymriah And Yescarta

With Novartis’s and Kite’s CAR T-cell therapies both expected to gain recommendations for pan-EU approval this week, discounts will need to be negotiated for these new treatments to reach the markets in Europe.

Topic cell-and-gene-therapy

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

CAR-T Therapy In Medicare: National Coverage Policy Could Come In 2019

18 May 2018

CAR-T Therapy In Medicare: National Coverage Policy Could Come In 2019

Medicare begins analysis process for CAR-T cancer therapies in response to a request from United Healthcare for a national coverage policy.

Topic Cancer Cell and gene therapy

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Gene therapy

15 May 2018

Topic cell-and-gene-therapy

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。